Caplin Point Laboratories Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 17, 2026
- Posted by: Harsh Piplani
- Category: Results
Caplin Point Laboratories share price Rs 2,610.90 on 17 September 2026, up 1.08%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 179.00 crore. Q2 FY26 base a profit of Rs 160.00 crore.
Quick Answer
The Caplin Point Laboratories Q2 results date for FY27 is not confirmed, and Caplin Point Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE as of 17 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 534.00 crore in revenue and a profit of Rs 160.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Caplin Point Laboratories Q2 results FY27 announcement is the next scheduled earnings event for Caplin Point Laboratories Ltd., Caplin Point Laboratories manufactures and sells generic pharmaceutical formulations and active ingredients, with a large share of sales going to Latin American and other emerging markets.. The stock traded at Rs 2,610.90 on the NSE on 17 September 2026, up 1.08% from the previous close of Rs 2,583.00, about 9.3% below its 52-week high of Rs 2,877.30 and 74.0% above its 52-week low of Rs 1,500.30.
What makes the Caplin Point Laboratories Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 534.00 crore of revenue and a profit of Rs 160.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 610.00 crore and a profit of Rs 179.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Caplin Point Laboratories Q2 Results FY27 Date?
The Caplin Point Laboratories Q2 results date for FY27 is not confirmed. As of 17 September 2026, Caplin Point Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
Also read – Nazara Technologies Q2 Results FY27 Preview: Results Date, Expectations
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Caplin Point Laboratories Q2 results date becomes public through that filing rather than through any advance announcement.
The Caplin Point Laboratories Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Caplin Point Laboratories.
Caplin Point Laboratories Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Caplin Point Laboratories Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Caplin Point Laboratories. The Caplin Point Laboratories Q2 results watchlist below is built from what the company has actually reported and disclosed.
The Caplin Point Laboratories Q2 results arrive after a run of consistent, quarter-on-quarter growth heading into the September 2026 quarter. Revenue has risen every quarter over the last five, from Rs 510 crore in June 2025 to Rs 534 crore in September 2025, Rs 543 crore in December 2025, Rs 600 crore in March 2026, and Rs 610 crore in June 2026. Net profit has followed the same steady upward path, climbing from Rs 151 crore to Rs 179 crore across those same five quarters without a single down quarter. This kind of uninterrupted growth stands out compared with the more volatile patterns seen at some other companies reporting around the same time.
Operating margin has stayed remarkably steady through this run, holding close to 34% to 35% in every one of the last five quarters, which points to consistent pricing and cost control across the company’s generic pharmaceutical portfolio. Return on equity of 20.9% and return on capital employed of 24.2% are both strong, reflecting efficient use of capital in a business built around emerging-market generics and active pharmaceutical ingredients. Generic pharmaceutical exporters focused on Latin America and other emerging markets have generally benefited from steady demand and manageable competitive pressure in recent years, and Caplin Point’s margin consistency fits that broader sector pattern well, a useful backdrop for the Caplin Point Laboratories Q2 results. This kind of sector-wide steadiness is part of what will frame the Caplin Point Laboratories Q2 results once filed.
Also read – Premier Energies Q2 Results FY27 Preview: Results Date, Expectations
Heading into the September 2026 quarter, the Caplin Point Laboratories Q2 results will likely be judged on whether the company can extend its run of five straight quarters of higher revenue and higher net profit. With operating margin steady near 35% and return on equity above 20%, the business goes into the September 2026 quarter from a position of consistency rather than one needing a turnaround. Given how stable the recent trend has been, from Rs 510 crore to Rs 610 crore in revenue and Rs 151 crore to Rs 179 crore in net profit, the next quarter is likely to be read mainly as a continuation of that pattern.
Check Caplin Point Laboratories Ltd. Live Fundamentals on the Univest Screener
Caplin Point Laboratories Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Caplin Point Laboratories Ltd. reported revenue of Rs 610.00 crore in Q1 FY27, up 19.61% from Rs 510.00 crore in Q1 FY26, and a profit of Rs 179.00 crore at the net level, up 18.54% from Rs 151.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was up 1.67% over the March 2026 quarter figure of Rs 600.00 crore, and net profit was up 3.47% from Rs 173.00 crore in Q4 FY26. Operating margin stood at 35.0% in Q1 FY27 against 35.0% in the September 2025 quarter, which is the comparison the Caplin Point Laboratories Q2 results print will be read against.
Q2 FY26 Base: The Comparison Caplin Point Laboratories Q2 Results FY27 Must Beat
Caplin Point Laboratories Ltd. reported revenue of Rs 534.00 crore and a profit of Rs 160.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Caplin Point Laboratories Q2 results preview.
Net profit in that base quarter was below the Rs 179.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 534.00 crore sits below the Rs 610.00 crore of the June 2026 quarter, which frames how much sequential movement the Caplin Point Laboratories Q2 results print needs to show growth.
Caplin Point Laboratories Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 534.00 | 160.00 |
| Q3 FY26 (Dec 2025) | 543.00 | 166.00 |
| Q4 FY26 (Mar 2026) | 600.00 | 173.00 |
| Q1 FY27 (Jun 2026) | 610.00 | 179.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Caplin Point Laboratories Q2 results preview uses.
Revenue across those four quarters ranged from Rs 534.00 crore to Rs 610.00 crore, and net profit from Rs 160.00 crore to Rs 179.00 crore. That spread is the honest context for the Caplin Point Laboratories Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Caplin Point Laboratories Q2 Results FY27
The Caplin Point Laboratories Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Caplin Point Laboratories has already reported.
Five Straight Quarters Of Growth
Both revenue and net profit have risen in each of the last five quarters, with revenue up from Rs 510 crore to Rs 610 crore and net profit up from Rs 151 crore to Rs 179 crore. This unbroken growth streak is the standout feature ahead of the Caplin Point Laboratories Q2 results, since it shows the company has avoided the kind of quarter-to-quarter swings seen elsewhere in this reporting cycle, a point worth keeping in mind when the Caplin Point Laboratories Q2 results are filed.
Consistent Operating Margin
Operating margin has stayed in a tight 34% to 35% band across all five quarters, a level of consistency that is uncommon and points to stable pricing power and cost discipline in the company’s generics business. This steadiness reduces some of the uncertainty typically associated with the Caplin Point Laboratories Q2 results, since margin has not been a source of surprise in recent history.
Strong Return Ratios
Return on equity of 20.9% and return on capital employed of 24.2% are both well above the levels seen at several other companies in this batch, reflecting efficient capital use in Caplin Point’s export-focused generics business. These return ratios, combined with the steady growth trend, form the backdrop against which the market will view the Caplin Point Laboratories Q2 results.
Caplin Point Laboratories Q2 Results FY27: Share Price and Valuation Going Into the Print
Caplin Point Laboratories share price today is Rs 2,610.90 on the NSE, up Rs 27.90 or 1.08% from the previous close of Rs 2,583.00 on 17 September 2026, ahead of the Caplin Point Laboratories Q2 results announcement.
| Metric | Value (17 September 2026) |
|---|---|
| NSE Symbol | CAPLIPOINT |
| Current Market Price | Rs 2,610.90 |
| 52-Week High | Rs 2,877.30 |
| 52-Week Low | Rs 1,500.30 |
| Market Capitalisation | Rs 19842 crore |
| PE Ratio | 29.79 |
| PB Ratio | 5.89 |
| EPS (TTM) | Rs 87.64 |
| Book Value per Share | Rs 443.00 |
| Debt to Equity | 0.07 |
| Return on Equity | 20.90% |
| 50-Day Moving Average | Rs 2406.60 |
| 200-Day Moving Average | Rs 2021.57 |
| RSI (14) | 54.30 |
The stock trades above both its 50-day average of Rs 2406.60 and its 200-day average of Rs 2021.57, with a 14-day RSI of 54.30. None of this is a view on where the shares go once the Caplin Point Laboratories Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Caplin Point Laboratories Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Caplin Point Laboratories Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Caplin Point Laboratories Q2 results print in proportion.
- Revenue against the Rs 534.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 160.00 crore in that same quarter
- Operating margin against 35.0% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Caplin Point Laboratories Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Caplin Point Laboratories Q2 Results FY27
The Caplin Point Laboratories Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Caplin Point Laboratories Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Caplin Point Laboratories Q2 results FY27 print faces a base of Rs 534.00 crore in revenue and a profit of Rs 160.00 crore, with the most recent quarter having delivered Rs 610.00 crore and a profit of Rs 179.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Caplin Point Laboratories, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Caplin Point Laboratories Q2 Results FY27
What is the Caplin Point Laboratories Q2 results date for FY27?
Ans. The Caplin Point Laboratories Q2 results date for FY27 is not confirmed. Caplin Point Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE as of 17 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Caplin Point Laboratories Q2 results 2026 cover?
Ans. The Caplin Point Laboratories Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Caplin Point Laboratories Ltd. reports revenue, operating profit and net profit for that period, and the Caplin Point Laboratories Q2 results filing also carries the notes to the accounts.
What were the Caplin Point Laboratories Q1 FY27 results?
Ans. Caplin Point Laboratories Ltd. reported revenue of Rs 610.00 crore in Q1 FY27 and a profit of Rs 179.00 crore at the net level. Revenue was up 19.61% versus Q1 FY26 and net profit was up 18.54% from Rs 151.00 crore in Q1 FY26.
What were Caplin Point Laboratories Q2 FY26 results in the September 2025 quarter?
Ans. Caplin Point Laboratories Ltd. reported revenue of Rs 534.00 crore and a profit of Rs 160.00 crore in Q2 FY26. Operating margin was 35.0%. Those figures form the base for the Caplin Point Laboratories Q2 results FY27 comparison.
What are the main Caplin Point Laboratories Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Caplin Point Laboratories Q2 results expectations centre on revenue against the Rs 534.00 crore base, net profit against a profit of Rs 160.00 crore, operating margin against 35.0% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Caplin Point Laboratories share price today ahead of the Q2 earnings?
Ans. Caplin Point Laboratories share price is Rs 2,610.90 on the NSE as of 17 September 2026, up 1.08% from Rs 2,583.00. The stock is about 9.3% below its 52-week high of Rs 2,877.30 and 74.0% above its 52-week low of Rs 1,500.30, at a market capitalisation of Rs 19842 crore.
Is Caplin Point Laboratories a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Caplin Point Laboratories Ltd. The stock trades at a price-to-book ratio of 5.89 with a return on equity of 20.90%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
